Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovarian syndrome
- PMID: 2532471
- DOI: 10.1016/0002-9378(89)90954-x
Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovarian syndrome
Abstract
Peripheral androgen action largely determines the occurrence of hirsutism in women. Although serum 5 alpha-androstane-3 alpha, 17 beta-diol (3 alpha-diol) glucuronide signifies skin 5 alpha-reductase activity and has been used as a marker of hirsutism and peripheral androgen metabolism, other C19 androgen conjugates have recently been measured and may also be useful markers of hirsutism in women. In addition to normal controls we studied both hirsute and nonhirsute patients with polycystic ovarian syndrome who had similar levels of circulating androgen precursors. In these three groups we measured various C19 sulfates and glucuronides including serum 3 alpha-diol glucuronide. Serum androgen precursors were elevated, but were equal in the hirsute and nonhirsute patients. Serum androsterone sulfate and glucuronide, and 3 alpha-diol sulfate and glucuronide clearly differentiated the hirsute from the nonhirsute group. Among the conjugates, androsterone glucuronide was most reflective of the difference between the two groups (100.3 +/- 28.0 versus 42.9 +/- 4.0 ng/ml, p less than 0.05). In hirsute compared with nonhirsute patients with polycystic ovarian syndrome, serum 3 alpha-diol glucuronide was increased by the smallest amount (32%), followed by androsterone sulfate (38%), 3 alpha-diol sulfate (59%), and androsterone glucuronide with the largest increase (134%). Serum androsterone glucuronide and 3 alpha-diol glucuronide both correlated with androstenedione and dehydroepiandrosterone sulfate in hirsute women but not in nonhirsute women. These data suggest that besides serum 3 alpha-diol glucuronide, other C19 sulfate and glucuronide conjugates may reflect peripheral androgen action.
Similar articles
-
Androsterone sulfate: physiology and clinical significance in hirsute women.J Clin Endocrinol Metab. 1993 Jan;76(1):112-6. doi: 10.1210/jcem.76.1.8380602. J Clin Endocrinol Metab. 1993. PMID: 8380602
-
Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women.Fertil Steril. 1991 May;55(5):872-6. Fertil Steril. 1991. PMID: 1827073
-
Cutaneous application of an androstenedione gel as an in vivo test of 5 alpha-reductase activity in women.Fertil Steril. 1992 Oct;58(4):708-12. doi: 10.1016/s0015-0282(16)55316-3. Fertil Steril. 1992. PMID: 1426314
-
Disturbances of androgen secretion and metabolism in polycystic ovary syndrome.Clin Obstet Gynaecol. 1985 Sep;12(3):633-47. Clin Obstet Gynaecol. 1985. PMID: 2933204 Review.
-
Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies?J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 1;940:24-34. doi: 10.1016/j.jchromb.2013.09.022. Epub 2013 Sep 27. J Chromatogr B Analyt Technol Biomed Life Sci. 2013. PMID: 24140653 Review.
Cited by
-
The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne.J Endocrinol Invest. 2002 Oct;25(9):765-8. doi: 10.1007/BF03345509. J Endocrinol Invest. 2002. PMID: 12398233 Clinical Trial.
-
Suggesting disease associations for overlooked metabolites using literature from metabolic neighbors.Gigascience. 2022 Dec 28;12:giad065. doi: 10.1093/gigascience/giad065. Epub 2023 Sep 15. Gigascience. 2022. PMID: 37712592 Free PMC article.
-
A risk-benefit assessment of pharmacological therapies for hirsutism.Drug Saf. 2001;24(4):267-76. doi: 10.2165/00002018-200124040-00004. Drug Saf. 2001. PMID: 11330656 Review.
-
Preparation and clinical evaluation of Finastride gel in the treatment of idiopathic Hirsutism.J Drug Assess. 2015 Jun 18;4(1):12-8. doi: 10.3109/21556660.2015.1056525. eCollection 2015. J Drug Assess. 2015. PMID: 27536457 Free PMC article.
-
Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.Rev Endocr Metab Disord. 2013 Jun;14(2):185-205. doi: 10.1007/s11154-013-9243-y. Rev Endocr Metab Disord. 2013. PMID: 23619762
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical